Four things to know · April 15, 2026
DSIP · Nasal spray
Delta Sleep-Inducing Peptide (Emideltide)
Nasal DSIP uses direct nose-to-brain transport via olfactory pathways, producing sleep pressure in 15 to 45 minutes.
Noticed in days · Full benefit in weeks
15-45 minutes
Sleep pressure typically develops. Much faster than injection.
Day 1-3
Improved sleep onset and quality commonly reported.
Week 1
Established sleep pattern improvements become consistent.
Week 2
Cumulative stress and mood benefits typically emerge.
Nasal DSIP uses direct nose-to-brain transport via olfactory pathways, producing sleep pressure in 15 to 45 minutes. Best for on-demand sleep support and acute stress relief. The classic slow-wave sleep architecture effects are stronger with injection, but nasal is dramatically more convenient and works faster when you need it.
Nasal spray protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Sleep induction | 200-300mcg | Once at bedtime |
| Stress relief | 150-200mcg | Twice daily |
| Neuroprotection | 300-400mcg | Daily |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Sleep pressure typically develops. Much faster than injection.
Improved sleep onset and quality commonly reported.
Established sleep pattern improvements become consistent.
Cumulative stress and mood benefits typically emerge.
What to know
- ⚠Can cause temporary nasal irritation or dryness
- ⚠Absorption varies with nasal congestion. Skip if actively congested
- ⚠Not suitable for chronic sinusitis
- ⚠Nasal formulations degrade faster than injectable. Use within 10 days of reconstitution
- ⚠Store upright in the refrigerator
- ⚠Use caution if combining with opioid medications or GABA-active drugs
How DSIP works
DSIP modulates several neurotransmitter systems at once. It enhances GABA signaling (your brain's primary calming chemical), interacts with NMDA receptors, and engages the endogenous opioid system. It also helps regulate the HPA axis, your body's stress-response pathway, which is why people commonly report both better sleep and lower daytime stress. The nasal route adds a second pathway: olfactory transport that delivers the peptide directly into the central nervous system, producing faster onset than subcutaneous injection.
Key benefits
- ✓Enhances deep slow-wave sleep without sedation
- ✓Shortens time to fall asleep and reduces night awakenings
- ✓Calms the stress response by modulating cortisol and the HPA axis
- ✓No tolerance, dependence, or withdrawal reported across 50 years of research
- ✓Supports natural sleep architecture rather than forcing unconsciousness
- ✓Under FDA review for insomnia, opioid withdrawal, and narcolepsy
Regulatory status
Category 2 (listed by the FDA as Emideltide). The FDA's pharmacy compounding advisory committee is scheduled to review DSIP on July 24, 2026, for potential addition to the 503A bulks list. The uses under review: opioid withdrawal, chronic insomnia, and narcolepsy. Originally discovered in 1974, one of the oldest peptides on the July 2026 agenda.
KEY RESEARCH · 5 PAPERS CITED
Schneider-Helmert D, Schoenenberger GA
Experientia
1983
Kovalzon VM, Strekalova TV
Journal of Neurochemistry
2006
Graf MV, Kastin AJ
Peptides
1984
Research team (PCAC docket)
PCAC FDA-2025-N-6895
2021
Multiple
Neuroendocrinology
1988
The Pep Dispatch
Follow the evidence on DSIP as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.